Correction to: Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3 (Cancer Gene Therapy, (2014), 21, 7, (290-296), 10.1038/cgt.2014.29);Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3

Cancer Gene Therapy

Volumn 21, Issue 7, 2014, Pages 290-296

  Gan, R ^a   Yang, Y ^a   Yang, X ^a   Zhao, L ^a   Lu, J ^a,b,c   Meng, Q H ^d  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Zhejiang Provincial Key Laboratory of Medical Genetics   (China)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ESTROGEN RECEPTOR; MICRORNA 221; MICRORNA 222; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; MICRORNA; MIRN221 MICRORNA, HUMAN; MIRN222 MICRORNA, HUMAN; TIMP3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSFECTION; UP-REGULATION;

EID: 84904748161     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/s41417-023-00672-5     Document Type: Erratum

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30
2. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011; 62: 233-247
3. Giacinti L, Claudio PP, Lopez M, Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006; 11: 1-8
4. Patani N, Martin LA. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. Mol Cell Endocrinol 2014; 382: 683-694
5. Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C et al. Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 2011; 286: 42292-42302
6. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355
7. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297
8. Iorio MV, Croce CM. MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol 2009; 27: 5848-5856
9. Lagos-Quintana M, Rauhut R, Yalcin A, Mever J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-739
10. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005; 15: 563-568
11. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269
12. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007; 23: 175-205
13. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-Transcriptional regulation by microRNAs: Are the answers in sight?. Nat Rev Genet 2008; 9: 102-114
14. Iorio MV, Casalini P, Piovan C, Braccioli L, Taqliabue E. Breast cancer and micro- RNAs: Therapeutic impact. Breast 2011; 20(Suppl 3): S63-S70
15. Raouf A, Zhao Y, To K, Sting J, Delaney A, Barbara M et al. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 2008; 3: 109-118
16. Kendrick H, Regan JL, Magnay FA, Grigoriadis A, Mitsopoulos C, Zvelebil M et al. Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 2008; 9: 591
17. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122: 6-7
18. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010; 5: E13735
19. Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP, White BA. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat 2012; 132: 75-85
20. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL et al. MicroRNA- 221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283: 29897-29903
21. Zhang L, Wang T, Wright AF, Suri M, Schwartz CE, Stevenson RE et al. A microdeletion in Xp11.3 accounts for co-segregation of retinitis pigmentosa and mental retardation in a large kindred. Am J Med Genet A 2006; 140: 349-357
22. Zhang C, Kang C, You Y, Pu P, Yang W, Zhao P et al. Co-suppression of miR-221/ 222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Int J Oncol 2009; 34: 1653-1660
23. Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T et al. Robust global micro- RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 2009; 89: 597-606
24. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14: 2348-2360
25. Zhang J, Han L, Ge Y, Zhou X, Zhang A, Zhang C et al. miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. Int J Oncol 2010; 36: 913-920
26. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107: 264-269
27. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009; 16: 498-509
28. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573
29. Cruz-Munoz W, Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008; 45: 291-338
30. Ahonen M, Ala-Aho R, Baker AH, George SJ, Grénman R, Saarialho-Kere U et al. Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol Ther 2002; 5: 705-715
31. Edwards DR. TIMP-3 and endocrine therapy of breast cancer: An apoptosis connection emerges. J Pathol 2004; 202: 391-394
32. Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005; 591: 247-263
33. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Over SL et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66: 11954-11966
34. Baigude H, Rana TM. Interfering nanoparticles for silencing microRNAs. Methods Enzymol 2012; 509: 339-353
35. Lambertini E, Lisignoli G, Torreggiani E, Manferdini C, Gabusi E, Franceschetti T et al. Slug gene expression supports human osteoblast maturation. Cell Mol Life Sci 2009; 66: 3641-3653
36. Zampieri D, Nora LC, Basso V, Camassola M, Dillon AJ. Validation of reference genes in Penicillium echinulatum to enable gene expression study using real-Time quantitative RT-PCR. Curr Genet 2014 (e-pub ahead of print
37. Chen JL, Chang CJ, Wang JY, Wen CS, Tseng LM, Chang WC et al. In vitro and in vivo effects of Jia-Wei-Xiao-Yao-San in human breast cancer MCF-7 cells treated with tamoxifen. Integr Cancer Ther 2014 (e-pub ahead of print
38. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008; 283: 31079-31086
39. Span PN, Lindberg RL, Manders P, Tjan-Heijnen VC, Heuvel JJ, Beex LV et al. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol 2004; 202: 395-402
40. Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS et al. Tumour-Associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 2009; 11: R24
41. Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221/222 microRNA families: Opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia 2012; 17: 65-77
42. Hsu SH, Motiwala T, Roy S, Claus R, Mustafa M, Plass C et al. Methylation of the PTPRO gene in human hepatocellular carcinoma and identification of VCP as its substrate. J Cell Biochem 2013; 114: 1810-1818
43. Si ML, Zhu S, Wu H, Lu Z, Wu F. MoYY. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-2803
44. Chan JH, Lim S, Wong WS. Antisense oligonucleotides: From design to therapeutic application. Clin Exp Pharmacol Physiol 2006; 33: 533-540
45. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C et al. Silencing of microRNA families by seed-Targeting tiny LNAs. Nat Genet 2011; 43: 371-378
46. Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 2011; 71: 7608-7616
47. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130: 2113-2129